Compare iShares Global Clean Energy ETF (ICLN) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Global Clean Energy ETF vs Merck & Co., Inc. — how do they compare? iShares Global Clean Energy ETF trades at $18.41, while Merck & Co., Inc. trades at $133.45 (market cap $321.77B). The key difference: Merck & Co., Inc. pays a 2.61% dividend while iShares Global Clean Energy ETF pays none, and Merck & Co., Inc. is trading nearer its 52-week high, iShares Global Clean Energy ETF nearer its low. Which is the better fit depends on your goals.
| ICLN | MRK | |
|---|---|---|
52-Week High | $23.75 | $131.84 |
52-Week Low | $13.66 | $77.60 |
Market Cap | — | $321.77B |
Sector | — | Health |
Enterprise Value | — | $368.53B |
Dividend Yield | — | 2.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ICLN is trading at $18.395, up 1.74% today, with a bearish technical signal from moving averages. The ETF provides exposure to 105 global renewable energy companies but faces competition from traditional energy ETFs offering lower fees and higher yields. Recent news highlights clean energy's 25% gains in 2026, though policy uncertainties and geopolitical tensions pose risks.
The outlook remains mixed with structural growth in clean energy demand balanced against regulatory headwinds and expense ratio disadvantages. Key opportunities include global energy transition trends, while risks involve U.S. permit delays and Chinese supply chain tensions affecting solar development.
Merck & Co. (MRK) trades at $133.64, up 2.09% today, with a bullish technical signal from moving averages and strong institutional buying interest. The company reported solid earnings beats in recent quarters, with Q3 2026 EPS expected at $2.27. Revenue for 2025 reached $65.01B, and net income was $18.25B, though the P/E ratio of 104.34 suggests high valuation expectations. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline.
Outlook: MRK's growth is supported by strategic acquisitions and a dominant oncology franchise, but risks include high valuation multiples and competitive pressures. The consensus price target of $140.36 implies modest upside, with 68% of analysts rating it a Buy. Investors should monitor execution on the Terns integration and Q3 earnings results for catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Global Clean Energy ETF
The index is designed to track the performance of approximately 100 clean energy-related companies. The fund generally invests at least 80% of its assets in the component securities of the target index. The index may invest up to 20% of its assets in certain futures, trading options and swap contracts, cash and cash equivalents, as well as in securities not included in the index. It is non-diversified.
Read more on ICLN →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
